Table 2 Meta-analysis of HER2 amplification in patients with pancreatic cancer
Clinicopathological parameters | No. of studies | Cases | Model | OR | 95 % CI | P value for OR | P value for heterogeneity |
|---|---|---|---|---|---|---|---|
Age (≤60/>60) | 3 | 172 | R | 0.71 | 0.10–5.21 | 0.74 | 0.12 |
Gender (male/female) | 5 | 691 | F | 1.25 | 0.66–2.36 | 0.49 | 0.60 |
Location (head/other) | 2 | 556 | R | 7.58 | 0.60–95.35 | 0.12 | 0.08 |
Differentiation (well + moderate/poorly) | 6 | 726 | F | 0.81 | 0.42–1.60 | 0.55 | 0.33 |
Lymph node metastasis (yes/no) | 4 | 696 | F | 1.10 | 0.59–2.07 | 0.76 | 0.96 |
T stage (T1 + T2/T3 + T4) | 2 | 86 | F | 0.74 | 0.34–1.62 | 0.16 | 0.45 |
TNM (I + II/III + IV) | 4 | 645 | R | 0.87 | 0.14–5.63 | 0.89 | 0.04 |